TG THERAPEUTICS, INC. (TGTX)

Every figure this model derived for TGTX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 491,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 552,248,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,145,687,000 AssetsCurrent 2026-06-30
current liabilities 268,493,000 LiabilitiesCurrent 2026-06-30
equity 604,083,000 StockholdersEquity 2026-06-30
interest expense 37,492,000 InterestExpenseNonoperating 2026-06-30
ocf 17,876,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 799,536,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 81,162,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TGTX on one particular measure came for.

RatioValue
cash operating margin27.22
current ratio4.55
current ratio reported4.27
deferred revenue growth-29.63
dilution pct0.67
ebit yoy58.8
fcf margin2.17
growth cv1.31
interest cover3.64
net debt ebitda1.42
operating margin17.05
owner earnings margin-7.98
revenue growth76.08
revenue growth per share74.91
roic13.51
rule of 4093.13
sbc pct revenue10.15

What to be careful about

What this model itself distrusts about TGTX's figures. Written by the derivation as it ran, not added afterwards.